Research shows potential to reposition drugs in new indications

There are hundreds of new commercial opportunities to reposition patented drugs and drug candidates into novel indications, with significant near-term additional revenue potential for pharmaceutical companies.

That is a finding from analysis carried out by PrecisionLife, a UK company generating the deepest insights into disease biology to create novel precision medicine opportunities in chronic diseases.

"The successful global effort to find effective interventions for the most severe COVID-19 patients demonstrated the value of re-using current drugs"Careful indication extension or repositioning of drugs coupled with patient stratification biomarkers to identify responders can provide a faster, cheaper and derisked route to the approval of new therapies, with major benefits to patients with unmet medical needs, according to the analysis.